Quantum BioPharma Announces Corporate Updates
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, announced several corporate updates. The company settled $26,812.50 USD in debt through the issuance of 1,102 Class B Shares at $24.33 USD per share.
The Board granted 800 RSUs each to Clinical Advisors Peter Stys and Jack Antel, with vesting tied to regulatory milestones for Lucid MS clinical trials. Additionally, Kevin Malone's Board Advisor Agreement was terminated effective August 15, 2025.
Quantum BioPharma (NASDAQ: QNTM), una società biofarmaceutica focalizzata su disturbi neurodegenerativi e metabolici, ha annunciato alcuni aggiornamenti aziendali. La società ha estinto $26.812,50 USD di debito mediante l'emissione di 1.102 azioni di Classe B a $24,33 USD per azione.
Il Consiglio ha assegnato 800 RSU ciascuno ai consulenti clinici Peter Stys e Jack Antel, con il vesting collegato a milestone regolatorie per le sperimentazioni cliniche di Lucid MS. Inoltre, l'accordo di consulenza in Board con Kevin Malone è stato terminato con effetto dal 15 agosto 2025.
Quantum BioPharma (NASDAQ: QNTM), una compañía biofarmacéutica centrada en trastornos neurodegenerativos y metabólicos, anunció varias actualizaciones corporativas. La compañía saldó $26,812.50 USD de deuda mediante la emisión de 1.102 acciones Clase B a $24.33 USD por acción.
La Junta otorgó 800 RSU cada uno a los asesores clínicos Peter Stys y Jack Antel, con el devengo vinculado a hitos regulatorios para los ensayos clínicos de Lucid MS. Además, el acuerdo de asesoría de la Junta con Kevin Malone se terminó con efecto el 15 de agosto de 2025.
Quantum BioPharma (NASDAQ: QNTM))은(는) 신경퇴행성 및 대사 질환에 주력하는 바이오제약사로 여러 기업 관련 업데이트를 발표했습니다. 회사는 1,102주의 클래스 B 주식을 주당 $24.33 USD에 발행하여 $26,812.50 USD의 부채를 상환했습니다.
이사회는 임상 자문위원인 Peter Stys와 Jack Antel에게 각각 800 RSU를 부여했으며, 이는 Lucid MS 임상시험의 규제적 마일스톤 달성에 따라 완전 취득됩니다. 또한 Kevin Malone의 이사회 자문 계약은 2025년 8월 15일부로 종료되었습니다.
Quantum BioPharma (NASDAQ: QNTM), une société biopharmaceutique axée sur les maladies neurodégénératives et métaboliques, a annoncé plusieurs mises à jour d'entreprise. La société a réglé 26 812,50 USD de dette par l'émission de 1 102 actions de classe B au prix de 24,33 USD par action.
Le conseil d'administration a attribué 800 RSU chacun aux conseillers cliniques Peter Stys et Jack Antel, avec un vesting lié à des jalons réglementaires pour les essais cliniques de Lucid MS. De plus, l'accord de conseiller du conseil avec Kevin Malone a été résilié avec effet au 15 août 2025.
Quantum BioPharma (NASDAQ: QNTM), ein biopharmazeutisches Unternehmen, das sich auf neurodegenerative und metabolische Erkrankungen konzentriert, gab mehrere unternehmensbezogene Neuigkeiten bekannt. Das Unternehmen beglich $26.812,50 USD an Verbindlichkeiten durch die Ausgabe von 1.102 Class-B-Aktien zu je $24,33 USD.
Der Vorstand gewährte den klinischen Beratern Peter Stys und Jack Antel jeweils 800 RSUs, deren Vesting an regulatorische Meilensteine für die Lucid-MS-Studien gebunden ist. Außerdem wurde die Board-Advisor-Vereinbarung mit Kevin Malone zum 15. August 2025 beendet.
- Debt settlement through equity issuance at $24.33 per share demonstrates financial management
- Strategic RSU grants tied to clinical milestones incentivize development of Lucid MS program
- Clear milestone-based vesting structure for RSUs aligned with FDA filing goals
- Departure of Board Advisor Kevin Malone after brief tenure (since July 1, 2025)
- Dilution from debt conversion to equity
- Additional potential dilution from RSU grants if milestones are met
TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:
Debt Settlement
On August 12, 2025, the board of directors of the Company (the “Board”) authorized the settlement of outstanding debt with one (1) creditor in the amount of
Grant of Restricted Stock Units
On August 15, 2025, the Board authorized and approved the grant of restricted share units (each, an “RSU”) pursuant to the Equity Incentive Plan. The Company granted 800 RSUs each to Peter Stys and Jack Antel (each a “Clinical Advisor”). The RSUs granted vest in accordance with the following schedule:
- 500 RSUs will vest to each Clinical Advisor when the Company has a filing application with the US FDA or an equivalent regulatory filing in another country for the start of a clinical Phase 2 trial for Lucid MS within 1 year of grant.
- 300 RSUs will vest to each Clinical Advisor when the Company receives a no objection letter or an equivalent regulatory approval from the US FDA or other regulatory institution permitting the start of the clinical trial.
Statutory Hold Period and Restrictions on Resale
The Creditor Shares and RSUs (and any Class B Shares issuable upon their settlement) are subject to a statutory hold period of four months and one day pursuant to the policies of the CSE. The RSU’s and Creditor Shares were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein.
Change to Advisory Board
Effective August 15, 2025, the Company terminated the Board Advisor Agreement dated July 1, 2025, with Kevin Malone, and as a result, Mr. Malone is no longer serving as an Advisor to the Company’s Board of Directors.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
What debt settlement did Quantum BioPharma (QNTM) announce in August 2025?
How many RSUs did Quantum BioPharma (QNTM) grant to its Clinical Advisors?
What are the vesting conditions for Quantum BioPharma's (QNTM) RSU grants?
Who left Quantum BioPharma's (QNTM) Advisory Board in August 2025?
